PCN21 Disease Burden of Multiple Myeloma UNDER the Current Treatment Pattern in China
Q. Gong,C. Chen,L. Yan,H. Zhan,Y. Chen,W. Chen
DOI: https://doi.org/10.1016/J.VHRI.2020.07.071
2020-01-01
Value in Health Regional Issues
Abstract:To estimate the disease burden of multiple myeloma (MM) under the current treatment pattern in China. A decision-analytic model was constructed to simulate the Chinese patients with MM and the age and gender-matched Chinese general population over lifetime time horizon for the differences in overall survival, quality-adjusted life years (QALY), and lifetime direct medical costs. A literature search was conducted to identify appropriate evidence to estimate the model variables. Base case analysis and sensitivity analysis were conducted for the point estimations and uncertainty of the disease burden of MM. The Chinese MM patients were associated with reduced average overall survival by 15.043 years (5.934 years vs. 20.977 years), reduced average QALY by 10.326 QALY (3.622 QALY vs. 13.948 QALY), and increased average life-time direct medical costs by ¥315,045 (¥442,233 vs. ¥127,188). The one-way sensitivity analysis suggested that the reduced QALY associated with MM was sensitive to patient age (change: 1.813 QALY), the utility of progressive disease (change: 0.480 QALY), the mortality of the progressive disease (difference: -0.369 QALY), and the treatment effects of autologous stem cell transplantation (change: -0.260 QALY). The increased lifetime direct medical costs associated with MM was sensitive to the rate of thalidomide maintenance therapy (change: ¥-93,662), patient body surface area (change: ¥58,832), drug acquisition costs of bortezomib (change: ¥54,412), and direct medical costs of managing progressive disease (change: ¥40,453).The probabilistic sensitivity analysis with 5,000 Monte Carlo simulations estimated the median and 95% credible interval of reduced QALY (-10.351 QALY, -11.584 QALY to -9.709 QALY) and increased lifetime direct medical costs (¥315,003, ¥308,017 to ¥318,954). The disease burden of MM in Chinese patients was characterized by reduced overall survival, reduced QALY, and increased medical costs that were sensitive to patient demographics, lenalidomide maintenance therapy, bortezomib drug costs, and progressive disease.